Curagen says 'encouraged' by belinostat trials

LONDON (MarketWatch) -- CuraGen Corp.
crgn
said it was "encouraged" by a Phase II trial evaluating intravenous belinostat for T-cell Lymphomas. It said Phase Ib trial evaluating intravenous belinostat in combination with paclitaxel and carboplatin has been broaded to include those with transitional cell cancer of the bladder. It's found an objective clinical response in patients taking NCI P7267 with micropapillary/borderline LMP ovarian carcinoma that is pending confirmation and review.

Intraday Data provided by SIX Financial Information and subject to terms of use.
Historical and current end-of-day data provided by SIX Financial Information.
All quotes are in local exchange time. Real-time last sale data for U.S. stock quotes reflect trades reported through Nasdaq only.
Intraday data delayed at least 15 minutes or per exchange requirements.